Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Lung Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 96 articles: HTML format

Single Articles

May 2025
1. HUANG DD, Yang JC
   Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
   J Clin Oncol. 2025 May 8:JCO2500997. doi: 10.1200/JCO-25-00997.
   PubMed    
   
   
   April 2025
2. DEREK DE-RUI H, Yang JC
   Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
   J Clin Oncol. 2025 Apr 25:JCO2500625. doi: 10.1200/JCO-25-00625.
   PubMed    
   
   
   
3. SCHYTTE T, Knap MM, Kristiansen C, Appelt AL, et al
   Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.
   J Clin Oncol. 2025 Apr 18:JCO2401386. doi: 10.1200/JCO-24-01386.
   PubMed     Abstract available
   
   
   
4. MIURA S, Tanaka H, Misumi T, Yoshioka H, et al
   Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
   J Clin Oncol. 2025 Apr 16:JCO2402007. doi: 10.1200/JCO-24-02007.
   PubMed     Abstract available
   
   
   
5. PEROL M, Li W, Pennell NA, Liu G, et al
   Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
   J Clin Oncol. 2025 Apr 3:JCO2500275. doi: 10.1200/JCO-25-00275.
   PubMed     Abstract available
   
   
   March 2025
6. THAWANI R, Bestvina CM, Vokes EE, Juloori A, et al
   Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
   J Clin Oncol. 2025 Mar 27:JCO2402355. doi: 10.1200/JCO-24-02355.
   PubMed    
   
   
   
7. WU Y, Bi N
   Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
   J Clin Oncol. 2025 Mar 21:JCO2402532. doi: 10.1200/JCO-24-02532.
   PubMed    
   
   
   
8. KONG FS, Hu C, Bradley JD, Machtay M, et al
   Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
   J Clin Oncol. 2025 Mar 21:JCO2500069. doi: 10.1200/JCO-25-00069.
   PubMed    
   
   
   
9. KINDLER HL, Ismaila N, Bazhenova L, Chu Q, et al
   Treatment of Pleural Mesothelioma: ASCO Guideline Update.
   J Clin Oncol. 2025;43:1006-1038.
   PubMed     Abstract available
   
   
   
10. SUN L, Marmarelis ME, Aggarwal C
    Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Mar 7:JCO2402624. doi: 10.1200/JCO-24-02624.
    PubMed     Abstract available
    
    
    February 2025
11. OWEN DH, Ismaila N, Ahluwalia A, Feldman J, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.
    J Clin Oncol. 2025 Feb 27:JCO2402785. doi: 10.1200/JCO-24-02785.
    PubMed     Abstract available
    
    
    
12. LEIGHL NB, Ismaila N, Durm G, Florez N, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.
    J Clin Oncol. 2025 Feb 27:JCO2402786. doi: 10.1200/JCO-24-02786.
    PubMed     Abstract available
    
    
    
13. GAUTSCHI O, Park K, Solomon BJ, Tomasini P, et al
    Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2025 Feb 21:JCO2402076. doi: 10.1200/JCO-24-02076.
    PubMed     Abstract available
    
    
    
14. PIOTROWSKA Z
    Making Progress Along the Challenging Road of Drug Development for Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Feb 5:JCO2402656. doi: 10.1200/JCO-24-02656.
    PubMed    
    
    
    January 2025
15. JANNE PA, Wang BC, Cho BC, Zhao J, et al
    First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
    J Clin Oncol. 2025 Jan 29:JCO2401269. doi: 10.1200/JCO-24-01269.
    PubMed     Abstract available
    
    
    
16. REMON J, Bortolot M, Bironzo P, Cortiula F, et al
    De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
    J Clin Oncol. 2025 Jan 21:JCO2402347. doi: 10.1200/JCO-24-02347.
    PubMed     Abstract available
    
    
    
17. WERR L, Bartenhagen C, Rosswog C, Cartolano M, et al
    TERT Expression and Clinical Outcome in Pulmonary Carcinoids.
    J Clin Oncol. 2025;43:214-225.
    PubMed     Abstract available
    
    
    
18. AWAD MM, Forde PM, Girard N, Spicer J, et al
    Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
    J Clin Oncol. 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239.
    PubMed     Abstract available
    
    
    
19. PARK CJ, Lee ATM, Ou SI
    ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Jan 7:JCO2402514. doi: 10.1200/JCO-24-02514.
    PubMed    
    
    
    
20. SANDS J, Ahn MJ, Lisberg A, Cho BC, et al
    Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
    J Clin Oncol. 2025 Jan 6:JCO2401349. doi: 10.1200/JCO-24-01349.
    PubMed     Abstract available
    
    
    December 2024
21. 
    Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Dec 20:JCO2402719. doi: 10.1200/JCO-24-02719.
    PubMed    
    
    
    
22. LUO LY, Xue W, Qumseya A, Vasquez JC, et al
    Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    J Clin Oncol. 2024;42:4263-4270.
    PubMed     Abstract available
    
    
    
23. SIKKEMA BJ, Baart SJ, Paats MS, Smit EF, et al
    Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials.
    J Clin Oncol. 2024 Dec 11:JCO2401579. doi: 10.1200/JCO-24-01579.
    PubMed     Abstract available
    
    
    November 2024
24. KALEMKERIAN GP, Khurshid H, Ismaila N
    Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Nov 20:JCO2402245. doi: 10.1200/JCO-24-02245.
    PubMed     Abstract available
    
    
    
25. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    PubMed    
    
    
    
26. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    PubMed    
    
    
    
27. 
    Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Nov 12:JCO2402413. doi: 10.1200/JCO-24-02413.
    PubMed    
    
    
    
28. BAZHENOVA L, Ismaila N, Abu Rous F, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.
    J Clin Oncol. 2024 Nov 12:JCO2402133. doi: 10.1200/JCO-24-02133.
    PubMed     Abstract available
    
    
    October 2024
29. LEIGHL NB, Akamatsu H, Lim SM, Cheng Y, et al
    Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
    J Clin Oncol. 2024;42:3593-3605.
    PubMed     Abstract available
    
    
    
30. KENMOTSU H
    Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non-Small Cell Lung Cancer: Old or New Regimen?
    J Clin Oncol. 2024 Oct 11:JCO2401921. doi: 10.1200/JCO-24-01921.
    PubMed    
    
    
    
31. LE X, Patel JD, Shum E, Baik C, et al
    A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
    J Clin Oncol. 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533.
    PubMed     Abstract available
    
    
    
32. SUN H, Li M, Huang W, Zhang J, et al
    Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Tria
    J Clin Oncol. 2024 Oct 7:JCO2302075. doi: 10.1200/JCO.23.02075.
    PubMed     Abstract available
    
    
    
33. OWEN D, Chapman CH
    Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.
    J Clin Oncol. 2024 Oct 4:JCO2401448. doi: 10.1200/JCO-24-01448.
    PubMed     Abstract available
    
    
    
34. KONG FS, Hu C, Pryma DA, Duan F, et al
    Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment (18)F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung C
    J Clin Oncol. 2024 Oct 4:JCO2400022. doi: 10.1200/JCO.24.00022.
    PubMed     Abstract available
    
    
    
35. COOPER AJ, Riely GJ
    Can We Find a Place for Trophoblast Cell Surface Antigen 2-Targeted Antibody-Drug Conjugates in Lung Cancer?
    J Clin Oncol. 2024 Oct 1:JCO2401900. doi: 10.1200/JCO-24-01900.
    PubMed    
    
    
    September 2024
36. 
    Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2024 Sep 13:JCO2401883. doi: 10.1200/JCO-24-01883.
    PubMed    
    
    
    
37. AHN MJ, Tanaka K, Paz-Ares L, Cornelissen R, et al
    Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
    J Clin Oncol. 2024 Sep 9:JCO2401544. doi: 10.1200/JCO-24-01544.
    PubMed     Abstract available
    
    
    
38. LOVLY CM
    New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.
    J Clin Oncol. 2024 Sep 4:JCO2401147. doi: 10.1200/JCO.24.01147.
    PubMed    
    
    
    
39. CAMIDGE DR, Bar J, Horinouchi H, Goldman J, et al
    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
    J Clin Oncol. 2024;42:3000-3011.
    PubMed     Abstract available
    
    
    August 2024
40. DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al
    Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
    J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553.
    PubMed     Abstract available
    
    
    
41. KETPUEAK T, Tan DSW, Popat S
    Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?
    J Clin Oncol. 2024 Aug 26:JCO2400829. doi: 10.1200/JCO.24.00829.
    PubMed    
    
    
    
42. YANG JC, Lee DH, Lee JS, Fan Y, et al
    Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor?Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Aug 22:JCO2302747. doi: 10.1200/JCO.23.02747.
    PubMed     Abstract available
    
    
    
43. GREER JA, Post KE, Chabria R, Aribindi S, et al
    Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer.
    J Clin Oncol. 2024 Aug 1:JCO2400048. doi: 10.1200/JCO.24.00048.
    PubMed     Abstract available
    
    
    July 2024
44. YANG JJ, Zhang Y, Wu L, Hu J, et al
    Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
    J Clin Oncol. 2024 Jul 26:JCO2302363. doi: 10.1200/JCO.23.02363.
    PubMed     Abstract available
    
    
    
45. PIKE LRG, Miao E, Boe LA, Patil T, et al
    Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668.
    PubMed     Abstract available
    
    
    
46. DALY ME, Singh N, Ismaila N
    Management of Stage III Non-Small Cell Lung Cancer: ASCO Rapid Recommendation Update.
    J Clin Oncol. 2024 Jul 23:JCO2401324. doi: 10.1200/JCO-24-01324.
    PubMed     Abstract available
    
    
    
47. DZIADZIUSZKO R, Rzyman W
    At the Crossroads of Local and Systemic Treatment of Operable Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jul 23:JCO2401099. doi: 10.1200/JCO.24.01099.
    PubMed    
    
    
    
48. ELKRIEF A, Montesion M, Sivakumar S, Hale C, et al
    Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jul 22:JCO2301488. doi: 10.1200/JCO.23.01488.
    PubMed     Abstract available
    
    
    
49. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    PubMed     Abstract available
    
    
    
50. BLAKELY CM, Urisman A, Gubens MA, Mulvey CK, et al
    Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    J Clin Oncol. 2024 Jul 19:JCO2400071. doi: 10.1200/JCO.24.00071.
    PubMed     Abstract available
    
    
    
51. PEROL M
    TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?
    J Clin Oncol. 2024 Jul 10:JCO2401043. doi: 10.1200/JCO.24.01043.
    PubMed    
    
    
    June 2024
52. WALIANY S, Lin JJ
    Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer.
    J Clin Oncol. 2024 Jun 28:JCO2401062. doi: 10.1200/JCO.24.01062.
    PubMed    
    
    
    
53. 
    Erratum: Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
    J Clin Oncol. 2024 Jun 17:JCO2401092. doi: 10.1200/JCO.24.01092.
    PubMed    
    
    
    
54. YU Y, Miao E, Pike LRG
    Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    J Clin Oncol. 2024;42:2107-2108.
    PubMed    
    
    
    
55. PARK S, Baldry R, Jung HA, Sun JM, et al
    Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
    J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
    PubMed     Abstract available
    
    
    
56. PEROL M, Solomon BJ, Goto K, Park K, et al
    CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
    PubMed     Abstract available
    
    
    
57. LI W, Xiong A, Yang N, Fan H, et al
    Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.
    J Clin Oncol. 2024 Jun 1:JCO2400731. doi: 10.1200/JCO.24.00731.
    PubMed     Abstract available
    
    
    May 2024
58. SOLOMON BJ, Liu G, Felip E, Mok TSK, et al
    Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
    J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581.
    PubMed     Abstract available
    
    
    
59. PAZ-ARES LG, Juan-Vidal O, Mountzios GS, Felip E, et al
    Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
    J Clin Oncol. 2024 May 31:JCO2400733. doi: 10.1200/JCO.24.00733.
    PubMed     Abstract available
    
    
    
60. OWEN DH, Ismaila N, Freeman-Daily J, Roof L, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.
    J Clin Oncol. 2024 May 30:JCO2400762. doi: 10.1200/JCO.24.00762.
    PubMed     Abstract available
    
    
    
61. MO DC, Chen L, Wu Y, Huang JF, et al
    PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 May 16:JCO2400230. doi: 10.1200/JCO.24.00230.
    PubMed    
    
    
    April 2024
62. SPIGEL DR, Dowlati A, Chen Y, Navarro A, et al
    RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
    J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110.
    PubMed     Abstract available
    
    
    
63. DAI W, Wang Y, Liao J, Wei X, et al
    Electronic Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial.
    J Clin Oncol. 2024 Apr 4:JCO2301854. doi: 10.1200/JCO.23.01854.
    PubMed     Abstract available
    
    
    March 2024
64. NEAL J, Pavlakis N, Kim SW, Goto Y, et al
    CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
    J Clin Oncol. 2024 Mar 29:JCO2302166. doi: 10.1200/JCO.23.02166.
    PubMed     Abstract available
    
    
    
65. POTTER AL, Xu NN, Senthil P, Srinivasan D, et al
    Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
    J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780.
    PubMed     Abstract available
    
    
    
66. KATHURIA H, Wiener RS
    Toward Racial Equity in Lung Cancer Screening Eligibility.
    J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351.
    PubMed    
    
    
    
67. RODRIGUEZ GM, Popat R, Rosas LG, Patel MI, et al
    Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study.
    J Clin Oncol. 2024 Mar 13:JCO2301045. doi: 10.1200/JCO.23.01045.
    PubMed     Abstract available
    
    
    February 2024
68. HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
    Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
    J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.
    PubMed    
    
    
    
69. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
    PubMed     Abstract available
    
    
    
70. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
    J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
    PubMed     Abstract available
    
    
    
71. PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
    Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
    J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
    PubMed     Abstract available
    
    
    
72. REMON J, Besse B, Aix SP, Callejo A, et al
    Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Feb 7:JCO2301521. doi: 10.1200/JCO.23.01521.
    PubMed     Abstract available
    
    
    January 2024
73. MOK T, Nakagawa K, Park K, Ohe Y, et al
    Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    J Clin Oncol. 2024 Jan 22:JCO2301017. doi: 10.1200/JCO.23.01017.
    PubMed     Abstract available
    
    
    
74. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    PubMed     Abstract available
    
    
    
75. RICCIUTI B, Lamberti G, Puchala SR, Mahadevan NR, et al
    Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 11:JCO2300580. doi: 10.1200/JCO.23.00580.
    PubMed     Abstract available
    
    
    
76. FENG YN, Xiao L, Xie GY
    Atezolizumab in Advanced Squamous Cell Carcinoma of the Penis.
    J Clin Oncol. 2024;42:242-243.
    PubMed    
    
    
    
77. MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    J Clin Oncol. 2024;42:47-58.
    PubMed     Abstract available
    
    
    December 2023
78. 
    Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2023 Dec 19:JCO2302574. doi: 10.1200/JCO.23.02574.
    PubMed    
    
    
    
79. DE VIS JB, Cmelak AJ, Osmundson EC
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
    J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
    PubMed    
    
    
    
80. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
    Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
    J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
    PubMed    
    
    
    
81. 
    Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518.
    PubMed    
    
    
    
82. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
    PubMed     Abstract available
    
    
    
83. TAN DSW, Felip E, de Castro G, Solomon BJ, et al
    Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
    J Clin Oncol. 2023 Dec 1:JCO2300980. doi: 10.1200/JCO.23.00980.
    PubMed     Abstract available
    
    
    November 2023
84. UPRETY D, Remon J, Peters S
    First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
    J Clin Oncol. 2023 Nov 30:JCO2301524. doi: 10.1200/JCO.23.01524.
    PubMed    
    
    
    
85. OHRI N, Jolly S, Cooper BT, Kabarriti R, et al
    Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial.
    J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627.
    PubMed     Abstract available
    
    
    
86. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    PubMed     Abstract available
    
    
    
87. MONK BJ, Colombo N, Tewari KS, Dubot C, et al
    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914.
    PubMed     Abstract available
    
    
    October 2023
88. PARK S, Kim TM, Han JY, Lee GW, et al
    A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04).
    J Clin Oncol. 2023 Oct 20:101200JCO2301891. doi: 10.1200/JCO.23.01891.
    PubMed     Abstract available
    
    
    
89. HENDRIKS LEL, Remon J
    Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Oct 12:JCO2301830. doi: 10.1200/JCO.23.01830.
    PubMed    
    
    
    
90. KHURSHID H, Ismaila N, Bian J, Dabney R, et al
    Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
    J Clin Oncol. 2023 Oct 11:JCO2301435. doi: 10.1200/JCO.23.01435.
    PubMed     Abstract available
    
    
    
91. GARON EB, Lu S, Goto Y, De Marchi P, et al
    Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
    J Clin Oncol. 2023 Oct 3:JCO2300910. doi: 10.1200/JCO.23.00910.
    PubMed     Abstract available
    
    
    September 2023
92. 
    Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849.
    PubMed    
    
    
    
93. GOTO K, Goto Y, Kubo T, Ninomiya K, et al
    Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2023 Sep 11:JCO2301361. doi: 10.1200/JCO.23.01361.
    PubMed     Abstract available
    
    
    
94. HOE HJ, Solomon BJ
    Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better.
    J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768.
    PubMed    
    
    
    
95. YU HA, Goto Y, Hayashi H, Felip E, et al
    HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
    J Clin Oncol. 2023 Sep 10:JCO2301476. doi: 10.1200/JCO.23.01476.
    PubMed     Abstract available
    
    
    August 2023
96. VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al
    Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.